Minute Insight: Senseonics Eversense E3 CGM Receives CE Mark, Launch Planned For Q3
Executive Summary
Sensonics received the CE mark for its next-generation E3 CGM with plans to launch in the third quarter. It will be facing stiff competition from CGM makers Dexcom and Abbott in the European market.
You may also be interested in...
Senseonics Projects Slow Growth In 2022 Despite FDA Approval Of Eversense E3 CGM
Senseonics announced the long-awaited FDA approval of its Eversense E3 implantable CGM, featuring a sensor that lasts up to six months. The company is also developing a one-year version of Eversense and a transmitter-less version, but the stock market is disappointed with its sales projections.
Akili Introduces Adult Version Of Video Game Therapy To Lessen ADHD Symptoms
Video game therapy developer Akili Interactive launched a mobile video game therapy to reduce ADHD symptoms in adults. The company plans to seek FDA clearance.
Novo Nordisk In Negotiations To Acquire Medical Device Maker Biocorp For About $165M (€154M)
After a nearly two-year collaboration, Novo Nordisk said it has begun talks to buy a controlling stake in French medical device company Biocorp.